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HEMATOLOGICAL DISEASES—Methods & Concepts
PHM8
ESTIMATING UTILITY VALUES FOR SELF-REPORTED JOINT
PAIN AND MOTION LIMITATION OUTCOMES IN ADULT
HEMOPHILIA PATIENTS-THE HEMOPHILIA UTILIZATION
GROUP STUDY-PART V (HUGS-V)
Wu J1, Nichol MB1, Globe D2, Gwadry-Sridhar F3, Ullman M4,
Johnson KA1
1University of Southern California, Los Angeles, CA, USA, 2Amgen,
Thousand Oaks, CA, USA, 3University of Western Ontario, London,
Ontario, Canada, 4Gulf States Hemophilia and Thrombophilia Center,
Houston,TX, USA
OBJECTIVES: To assess 1) the association between estimated-
utilities and outcomes of relevance to hemophilia patients joint
pain (JP) and motion limitation (ML), and 2) sensitivity of six
methods for estimating utilities to these outcomes. METHODS:
Questionnaires completed by HUGS-V adult patients provided
demographic, SF-12, and self-reported JP/ML data. Six esti-
mated-utilities were derived from the SF-12, including HUI3/VAS
item models (IM) and categorical models (CM) from the Sen-
gupta-Nichol-Globe, SF-6D (Brazier), and Lundberg VAS algo-
rithms. An analysis of covariance was used to determine
differences in mean estimated-utilities between categories of
JP/ML (none, mild, severe). Covariate adjusted effect sizes (ES)
were calculated for estimated-utilities between categories of
JP/ML. Covariates included age, education, employment status,
income, and hemophilia severity. RESULTS: Of the 143 patients,
37% reported severe JP, and 57% reported severe ML in at least
one joint. Mean age was 35.1 years (range 18.1 to 68.4). Mean
estimated-utilities ranged from 0.72 (SF-6D) to 0.77 (HUI3 CM).
The estimated-utilities were strongly correlated with each other
(r range 0.60 to 0.98, p < 0.0001) and were signiﬁcantly differ-
ent across the JP/ML categories (P < 0.0001). Patients reporting
mild JP/ML compared to no JP/ML, had medium ES (0.6 to 0.7),
although the HUI3 IM (ES = 1.0) and SF-6D (ES = 0.9) had large
ES. Severe JP/ML showed large effects (ES rang 1.1 to 2.1) com-
pared to no JP/ML. Utilities derived from each estimation
method were slightly different with a mean difference less than
0.05 for each paired set of methods. The utility scores were
ordered similarly across categories of JP/ML. CONCLUSION:
The medium to large ES imply the ability to measure moderate
to large clinically signiﬁcant differences in relevant hemophilia
outcomes. Although these ES have not incorporated distribution-
based outcomes, the estimated-utilities from the SF-12 appear to
be clinically meaningful, interpretable, and may be used for cost-
effectiveness studies in patients with hemophilia.
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OBJECTIVES: To assess the association between self-reported
barriers to care and self-reported health related quality of life
(HRQOL) in Hemophilia patients. METHODS: Data were
derived from HUGS-V. Parents/patients completed a standard-
ized interview, including demographic, barriers to care, and
either the PedsQL or SF-12. Overall barriers to care were
assessed from an item “In the past 12 months, has there ever
been a time that you needed hemophilia care but it was difﬁcult
to get it?” Then, eleven speciﬁc barriers were assessed. An analy-
sis of covariance, adjusting for age, education, employment,
income, and hemophilia severity, was used to determine differ-
ences in HRQOL between patients with and without barriers to
care. RESULTS: Data for 290 patients (50% adult and 62% with
severe hemophilia) were analyzed. Mean age was 9.9 years (chil-
dren) and 35.2 (adult). Forty-three (14.8%) patients reported
one to six barriers to hemophilia care. Mean SF-12 physical and
mental composite scores were not signiﬁcantly different between
patients with and without any barrier to care. Covariate adjusted
PedsQL subscale and total scores (except for physical summary)
were signiﬁcantly lower in those reporting barriers to care versus
no barriers to care. The score differences ranged from 7.5 (phys-
ical summary) to 23.5 (emotional function). Children who
reported two or more barriers to care had lower HRQOL scores
for psychosocial summary (61.6) and total score (67.9) when
compared with those who did not report barriers to care (86.5
and 87.6, respectively). The most frequently reported barriers to
care were “distance to the clinic” for both adults and children,
“insurance coverage” for adults, and “clinic schedule not con-
venient” for children. CONCLUSION: Preliminary data indicate
that barriers to care may have a signiﬁcant association with
HRQOL outcome in hemophilia patients, especially in children.
Identifying and resolving speciﬁed barriers may improve care
access and subsequently patient reported outcomes.
INDIVIDUAL’S HEALTH—Clinical Outcomes Studies
PIH1
EVALUATION OF CAUSES AND CONSEQUENCES OF
INJURIES IN CHILDREN
Angalakuditi M
Surveillance Data Inc, Plymouth Meeting, PA, USA
OBJECTIVES: To evaluate the common causes and conse-
quences of injury related admission to the hospital in children in
Western Australia. METHODS: A retrospective study was con-
ducted at a Pediatric Teaching Hospital of patients <18 years of
age hospitalized between 11/01/2002 and 12/31/2002. Patient
medical records were reviewed if their admission diagnosis was
injury related. Data collected from the medical record were date
of birth, sex, date of admission, date of discharge, and clinical
details such as diagnosis, procedure, causes of injury, and out-
comes of the injury. RESULTS: One hundred and eighty four
patients were admitted as a result of injury during the study
period. Of these, one neonate, six infants, thirty-eight toddlers,
one hundred and eleven children and twenty-eight teenagers in
this study. The common cause of injury-related hospital admis-
sion was due to falls (109, 59%). The other causes of injury were
crushed in 15 (8%) patients, spilling ﬂuids in 10 (5.4%), and
bites in 8 (4.3%) patients. The most common consequence of an
injury in children (43/111, 38.7%) and teenagers (12/28, 43%)
was bone fracture. However, head injuries are the most common
consequence of injury in toddlers (11/38, 29%), infants (5/6,
83.3%) and neonates (1/1, 100%). The radius/ulna (36/63,
57%) was the most common site for bone fractures. Majority
(32/37, 86.5%) of the patients who suffered head injuries were
diagnosed as minor. CONCLUSION: The main cause of injury
related admission to the hospital in children was due to a fall
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and the common consequences were fractures and head injuries.
The common bones fractured were the radius and ulna.
PIH2
E-PRESCRIBING REDUCES BEERS PRESCRIBING AMONG 
THE ELDERLY
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OBJECTIVES: The objective of this study was to assess the
impact of a PDA-e-prescribing tool (e-tool) on prescribing poten-
tially inappropriate drugs from the Beers List to the elderly. The
Beers List documents potentially inappropriate medications that
should be avoided or used with caution in patients over the age
of 65 years. METHODS: All prescription claims (N = 383,855)
from April 2002 through June 2005 were extracted for 14,557
plan participants aged 65 and older in which 70 of 3706 pre-
scribers received an e-tool. For each claim, we identiﬁed whether
the prescription was new and a Beers listed drug and whether
the prescriber was an e-tool user and a staff model physician. E-
tool use was split into before and after initiation. New prescrip-
tions were classiﬁed into 6 and 12-month variables using prior
eligibility. Rates were determined as Beers claims counts divided
by total claims. We ran chi-square tests and logistic regressions
incorporating these and selected demographic variables.
RESULTS: After initiating e-tool use, providers prescribed sig-
niﬁcantly fewer Beers drugs than before across all (7.87% vs.
9.13%, p < 0.0001) and new (6-month: 3.39% vs. 4.68%, p <
0.0056; 12-month: 3.05% vs. 4.78%, p < 0.0025) prescriptions;
their before rates did not differ signiﬁcantly from non-e-tool
providers (overall: 9.09% vs. 9.13%, p = 0.8702; 6-month:
5.04% vs. 4.66%, p = 0.5459; 12-month: 3.05% vs. 4.78%, 
p < 0.9317). Staff providers prescribed signiﬁcantly fewer Beers
drugs overall than non-staff providers (8.88% vs. 9.27%, p =
0.0002), but not for 6-month (5.08% vs. 4.49%, p = 0.0558) or
12-month (4.97% vs. 4.69%, p = 0.5816) new prescriptions.
Regressions, accounting for provider degree and specialty, par-
ticipant sex and age group, and geography, yielded similar
results. CONCLUSION: e-Tools providing Beers criteria can sig-
niﬁcantly reduce the prescribing of these drugs among the elderly.
Such reductions have been shown to reduce morbidity, mortal-
ity, and health care costs.
INDIVIDUAL’S HEALTH—Cost Studies
PIH3
COST-EFFECTIVENESS OF ORAL AND TRANSDERMAL
CONTRACEPTIVE METHODS
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OBJECTIVES: The objective of this study was to identify the
most cost-effective oral or transdermal contraceptives (CCs)
using a provider perspective. METHODS: A decision analytic
model was developed to compare the cost-effectiveness of oral
CCs, 3 mg drospirenone/0.02 mg Ethinylestradiaol (DRSP-EE),
0.18 mg norgestimate/0.025 mg ethinylestradiol (NO-EE), and 
1 mg norethindrone acetate/20 mcg ethinyl estradiol (NA-EE);
transdermal CC 6 mg norelgestromin/0.075 mg ethinyestradiol
(transdermal N-EE); and no contraceptive use in preventing a
pregnancy per patient per year. Direct medical costs were based
on average wholesale prices for drugs (Wolters-Kluwer, 2006),
and, physician, laboratory and hospital costs based on 2006
Medicare reimbursement rates. Probability data that included
compliance and pregnancy rates were extracted from random-
ized clinical trials and public resources such as the 2002 National
Survey of Family Growth. A probabilistic sensitivity analysis of
all free parameters was conducted through a Monte Carlo sim-
ulation. Key parameters were sampled from beta distributions.
RESULTS: In the base case, DRSP-EE was found to be the most
cost-effective strategy. DRSP-EE cost $688 compared to $766 for
NA-EE, $736 for transdermal N-EE, and $729 for NO-EE to
prevent a single pregnancy per patient per year. No contracep-
tive use was the least cost-effective strategy, resulting in approx-
imately $52,529 to prevent a single pregnancy per patient per
year. Monte Carlo sensitivity analysis conﬁrmed these ﬁndings.
Incremental cost-effectiveness analyses revealed that the use of
transdermal N-EE costs an additional $86,285 per patient per
year to be as effective as DRSP-EE. CONCLUSION: In terms of
cost-effectiveness, DRSP-EE dominated all contraceptive strate-
gies. The overarching component driving differences in cost-
effectiveness was related to direct medical costs associated with
pregnancy. These direct medical costs, in turn, were driven by
differential compliance and efﬁcacy rates that favored DRSP-EE.
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OBJECTIVES: Estimate annual direct (medical expenditure) and
indirect (absenteeism and short-term disability) costs for women
with uterine ﬁbroids (UF). METHODS: We compared 12-month
direct costs among women aged 18–54 with clinically-signiﬁcant,
symptomatic UF (admission, emergency visit, or >2 ofﬁce visits
>30 days apart with a UF diagnosis) to a 1 : 1 propensity score
matched cohort of women without UF, using the MarketScan
Commercial Claims and Encounters insurance database data
from for 2000–2004. We also compared indirect costs for the
sub-sample of women with available data. Exponential condi-
tional regression analysis controlled for confounding factors, and
costs were adjusted to 2004 levels. RESULTS: Sample sizes for
the direct and indirect costs analyses were 38,020 and 1820,
respectively. Mean 12-month direct costs for women in the UF
group were $11,720 vs. $3257 for controls (women without
diagnosed or treated ﬁbroids). Mean 12-month indirect costs
were $11,752 and $8083 for women in the UF group and con-
trols, respectively. Estimated direct costs attributable to UF were
therefore $8463 (p < 0.001) and indirect costs were $3669 (p <
0.001). Employers’ share of direct costs ranged from 84.1% to
87.5%. CONCLUSION: Direct and indirect costs of uterine
ﬁbroids represent a substantial burden to employers. Treatment
options aimed at reducing symptoms and resultant absenteeism
are needed to improve women’s health and productivity.
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SURGICAL COST OF PELVIC ORGAN PROLAPSE IN
GERMANY, FRANCE AND ENGLAND
Subramanian D1, Slack M2
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OBJECTIVES: To estimate the direct cost of surgical interven-
tions for Pelvic Organ Prolapse (POP) to the payers in Germany,
France and the National Health Service (NHS) in England.
